WG Biotech ApS - Dec 7, 2023 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
Director
Signature
WG Biotech ApS by /s/ Johan Wedell-Wedellsborg
Stock symbol
YMAB
Transactions as of
Dec 7, 2023
Transactions value $
$890,411
Form type
4
Date filed
12/11/2023, 05:25 PM
Previous filing
Dec 1, 2023
Next filing
Dec 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Purchase $40.2K +6.18K +0.14% $6.50 4.43M Dec 7, 2023 Direct F1
transaction YMAB Common stock Purchase $129K +18.5K +0.42% $6.99 4.45M Dec 8, 2023 Direct F2
transaction YMAB Common stock Purchase $721K +103K +2.31% $7.01 4.55M Dec 11, 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades each at price of $6.50. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed in multiple trades at prices ranging from $6.90 to $7.00. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $6.86 to $7.15. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Johan Wedell-Wedellsborg is the majority owner of WG Biotech ApS and has sole voting and dispositive power over the shares of the Issuer held by WG Biotech ApS. Mr. Wedell-Wedellsborg serves as a director of the Issuer. In connection therewith, WG Biotech ApS may be deemed to be a director by deputization of the Issuer solely for purposes of Section 16(a) of the Exchange Act. As a result, WG Biotech ApS is listed as a "Reporting Person" in Item 1 and the "Director" box is marked in Item 5 of this Form 4. This filing shall not be deemed an admission by Reporting Person on this Form 4 that such person is a director of the Issuer by deputization.